Avidity Biosciences Statistics

Total Valuation

RNA has a market cap or net worth of $3.54 billion. The enterprise value is $2.16 billion.

Market Cap	3.54B
Enterprise Value	2.16B

Important Dates

The last earnings date was Thursday, May 8, 2025, after market close.

Earnings Date	May 8, 2025
Ex-Dividend Date	n/a

Share Statistics

RNA has 120.54 million shares outstanding. The number of shares has increased by 58.13% in one year.

Current Share Class	120.54M
Shares Outstanding	120.54M
Shares Change (YoY)	+58.13%
Shares Change (QoQ)	+0.57%
Owned by Insiders (%)	0.85%
Owned by Institutions (%)	88.71%
Float	92.71M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	396.03
Forward PS	630.64
PB Ratio	2.66
P/TBV Ratio	2.66
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	242.13
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 16.91, with a Debt / Equity ratio of 0.00.

Current Ratio	16.91
Quick Ratio	16.69
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -34.19% and return on invested capital (ROIC) is -24.90%.

Return on Equity (ROE)	-34.19%
Return on Assets (ROA)	-22.47%
Return on Invested Capital (ROIC)	-24.90%
Return on Capital Employed (ROCE)	-31.53%
Revenue Per Employee	$22,831
Profits Per Employee	-$944,297
Employee Count	391
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +12.98% in the last 52 weeks. The beta is 0.99, so RNA's price volatility has been similar to the market average.

Beta (5Y)	0.99
52-Week Price Change	+12.98%
50-Day Moving Average	29.51
200-Day Moving Average	37.06
Relative Strength Index (RSI)	50.04
Average Volume (20 Days)	1,442,600

Short Selling Information

Short Interest	15.58M
Short Previous Month	15.48M
Short % of Shares Out	15.86%
Short % of Float	n/a
Short Ratio (days to cover)	8.36

Income Statement

In the last 12 months, RNA had revenue of $8.93 million and -$369.22 million in losses. Loss per share was -$3.03.

Revenue	8.93M
Gross Profit	-327.32M
Operating Income	-433.27M
Pretax Income	-228.68M
Net Income	-369.22M
EBITDA	-430.35M
EBIT	-433.27M
Loss Per Share	-$3.03

Full Income Statement

Balance Sheet

The company has $1.38 billion in cash and $5.97 million in debt, giving a net cash position of $1.37 billion or $11.40 per share.

Cash & Cash Equivalents	1.38B
Total Debt	5.97M
Net Cash	1.37B
Net Cash Per Share	$11.40
Equity (Book Value)	1.33B
Book Value Per Share	11.03
Working Capital	1.35B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$355.32 million and capital expenditures -$9.90 million, giving a free cash flow of -$365.22 million.

Operating Cash Flow	-355.32M
Capital Expenditures	-9.90M
Free Cash Flow	-365.22M
FCF Per Share	-$3.03

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-4,853.43%
Pretax Margin	-4,135.99%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

RNA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-58.13%
Shareholder Yield	-58.13%
Earnings Yield	-10.44%
FCF Yield	-10.33%

Analyst Forecast

The average price target for RNA is $67.92, which is 131.57% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$67.92
Price Target Difference	131.57%
Analyst Consensus	Strong Buy
Analyst Count	12
Revenue Growth Forecast (5Y)	157.39%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

RNA has an Altman Z-Score of 18.01 and a Piotroski F-Score of 2.

Altman Z-Score	18.01
Piotroski F-Score	2